- Home
- BRT vs ANL Comparison
BRT vs ANL Comparison
Compare BRT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRT | ANL |
|---|---|---|
| Founded | 1972 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.3M | 325.5M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BRT | ANL |
|---|---|---|
| Price | $14.12 | $7.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $19.75 | $16.00 |
| AVG Volume (30 Days) | 23.4K | ★ 215.2K |
| Earning Date | 06-24-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $14.00 | $0.88 |
| 52 Week High | $18.50 | $12.09 |
Technical Indicators
Market Signals| Indicator | BRT | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 47.12 |
| Support Level | N/A | $7.21 |
| Resistance Level | $15.11 | $9.98 |
| Average True Range (ATR) | 0.32 | 1.05 |
| MACD | -0.06 | -0.31 |
| Stochastic Oscillator | 0.00 | 25.68 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.